NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma ...

For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...

Citius Oncology reports positive results from phase 1 study of Lymphir in combo with pembrolizumab in relapsed or refractory gynaecologic cancers: Cranford, New Jersey Friday, Mar ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 ...

Genmab A/S (NASDAQ:GMAB) executives outlined a slate of late-stage clinical catalysts expected in 2026, highlighting multiple ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY(R) ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...

Price transparency compliance is often “in-form” rather than “in-spirit,” with many machine-readable files failing to provide complete, accurate, and usable drug pricing data. Reform priorities ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...